Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/15/2021 06/16/2021 06/17/2021 06/18/2021 06/21/2021 Date
110.41(c) 110.06(c) 111.63(c) 110.33(c) 111.72 Last
5 398 786 7 051 524 5 967 581 8 832 123 1 679 674 Volume
-0.06% -0.32% +1.43% -1.16% +1.26% Change
More quotes
Financials (USD)
Sales 2021 39 425 M - -
Net income 2021 5 861 M - -
Net Debt 2021 9 307 M - -
P/E ratio 2021 33,7x
Yield 2021 1,54%
Sales 2022 39 571 M - -
Net income 2022 6 574 M - -
Net Debt 2022 7 164 M - -
P/E ratio 2022 30,3x
Yield 2022 1,65%
Capitalization 196 B 196 B -
EV / Sales 2021 5,21x
EV / Sales 2022 5,14x
Nbr of Employees 109 000
Free-Float 89,0%
More Financials
Company
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Company focuses on cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicine. It offers products,... 
More about the company
Ratings of Abbott Laboratories
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ABBOTT LABORATORIES
09:47aU.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel d..
RE
06/11INSIDER TRENDS : Insider at Abbott Laboratories Tax Sale Continues 90-Day Sellin..
MT
06/11ABBOTT LABORATORIESá : Maintains Quarterly Dividend of $0.45 Per Share, Payable ..
MT
06/11ABBOTTá : Declares 390th Consecutive Quarterly Dividend
PR
06/07INSIDER TRENDS : Abbott Laboratories Insider Sale for Taxes Adds to 90-Day Selli..
MT
06/07INSIDER TRENDS : Insider at Abbott Laboratories Makes Tax Sale Extends 90-Day Se..
MT
06/07ABBOTT LABORATORIESá : and Walgreens Launch Pilot Program to Increase Access to ..
PU
06/04S&P 500 Posts 0.6% Weekly Increase as May Jobs Climb But Miss Expectations; E..
MT
06/04ABBOTT LABORATORIESá : Confirms capacity to support expanded use of heartmate 3 ..
AQ
06/03Abbott Labs Plans Restructuring Due to Changes in Covid-19 Testing Demand
DJ
06/03ABBOTT LABORATORIESá : R&D pipeline continues to be highly productive, with a st..
PU
06/03ABBOTT LABORATORIESá : Costs Associated with Exit or Disposal Activities, Regula..
AQ
06/03Medtronic to Stop Selling HVAD Implantable Heart Pump Over Safety Concerns
DJ
06/03ABBOTT LABORATORIESá : Says It Has Capacity to Support Expanded Use of Heart Pum..
MT
06/03ABBOTTá : Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart ..
PR
More news
News in other languages on ABBOTT LABORATORIES
06/04MORNING BRIEFING - USA/Asien -2-
06/02Pause en vue en Europe sur fond d'optimisme ambiant
06/01WALL STREET STOCK EXCHANGE : Wall Street sluit verdeeld
06/01WALL STREET STOCK EXCHANGE : Wall Street blijft dichtbij huis
06/01LA VALEUR DU JOUR À WALL STREET ABBO : le recul du Covid, mauvaise aiffaire
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Stock Trading Strategies
ABBOTT LABORATORIES - 01/20
Close to a key resistance level
BUY
More Stock Trading Analysis
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 124,86 $
Last Close Price 110,33 $
Spread / Highest target 43,2%
Spread / Average Target 13,2%
Spread / Lowest Target -12,1%
EPS Revisions
Managers and Directors
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive Vice President
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES0.77%196 037
MEDTRONIC PLC5.20%165 794
BECTON, DICKINSON AND COMPANY-3.87%69 953
HOYA CORPORATION1.26%48 451
ALIGN TECHNOLOGY, INC.12.59%47 612
SARTORIUS STEDIM BIOTECH S.A.30.77%41 615